基体和外端蛋白 (BET):生物功能,疾病和向治疗
Zhi-Qiang Wang1, Zhao-Cong Zhang1, Yu-Yang Wu2
1Department of Gynecology Oncology, Harbin Medical University Cancer Hospital, Harbin, 150086, China.
Signal transduction and targeted therapy
|November 5, 2023
概括
作为表观遗传抗癌疗法,BET抑制剂显示出有前途,但单独有效性有限. 将BET抑制剂与其他药物结合,为增强癌症治疗提供了一个有希望的策略.
科学领域:
- 在瘤学瘤学.
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- BET蛋白质作为表观遗传解释者,调节基因表达,这对癌症发展至关重要.
- BET抑制剂代表了癌症治疗的新型表观遗传方法.
- 初步的临床试验表明抗癌潜力但有限的单一治疗疗效.
研究的目的:
- 审查BET蛋白的功能及其在癌症中的向.
- 检查小分子BET抑制剂的进展和临床发现.
- 探索BET抑制剂的组合策略和抵抗机制.
主要方法:
- 关于BET蛋白功能,癌症向和抑制剂开发的文献综述.
- 对临床前数据和初步临床试验结果的分析.
- 研究耐药机制,不良事件和协同作用的药物组合.
主要成果:
- BET 抑制剂显示出抗癌潜力,但在单一治疗中面临挑战.
- 了解耐药机制和不良事件对于有效使用至关重要.
- 目前正在探索与其他药物的多种协同组合.
结论:
- 将BET抑制剂与其他抗癌药物和下一代药物的结合具有显著的潜力.
- 优化组合疗法是推动瘤学中BET蛋白向的关键.
- 当明智地使用时,BET抑制剂是一种有前途的策略,具有强大的抗瘤作用.
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Canonical Wnt Signaling Pathway
8.8K
The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which...
8.8K
Master Transcription Regulators
6.9K
Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
6.9K


